Nedaplatin
| |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C2H8N2O3Pt |
Molar mass | 303.17 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.
Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.[2]
References
- ↑ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-related Cancer. 22 (4): R219–33. doi:10.1530/ERC-15-0237. PMID 26113607.
- ↑ Johnstone, Timothy C.; Park, Ga Young; Lippard, Stephen J. (2014-01-01). "Understanding and Improving Platinum Anticancer Drugs – Phenanthriplatin". Anticancer research. 34 (1): 471–476. ISSN 0250-7005. PMC 3937549. PMID 24403503.
- (in Japanese) Aqupla アクプラ (PDF) Shionogi & Co. March 2007.
External links
- (in Japanese) Official Shionogi & Co. Website
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.